Get started
Author

Dirk Huebner

Observed name: Huebner, Dirk
Observed institutions: Jagiellonian University, Fox Chase Cancer Center, BC Cancer Agency, Roswell Park Comprehensive Cancer Center, City Of Hope National Medical Center, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, University of British Columbia, University of California, Los Angeles, New York Medical College, Washington University in St. Louis, University of Alabama at Birmingham, Instytut Hematologii i Transfuzjologi, Aptevo Therapeutics (United states), Duke Medical Center, Stanford Medicine, Mersana Therapeutics (United States), UAB Medicine, Takeda Oncology (United States), Takeda (Japan), The University of Texas Southwestern Medical Center, Vanderbilt University Medical Center
OpenAlex ID: A5111959028
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
2017 · Joseph M. Connors, Wojciech Jurczak, et al. · New England Journal of Medicine · 789
PDF
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
2015 · Craig H Moskowitz, Auayporn Nademanee, et al. · The Lancet · 744
PDF
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
2017 · H Miles Prince, Youn H Kim, et al. · The Lancet · 588
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
2016 · Robert Chen, Ajay K. Gopal, et al. · Blood · 395
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
2013 · Anas Younes, Joseph M Connors, et al. · The Lancet Oncology · 270
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
2017 · Barbara Pro, Ranjana Advani, et al. · Blood · 246
PDF
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
2014 · Nancy L Bartlett, Robert Chen, et al. · Journal of Hematology & Oncology · 181
PDF
Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30 + Peripheral T-Cell Lymphomas: Results of a Phase I Study
2014 · Michelle A. Fanale, Steven M. Horwitz, et al. · Journal of Clinical Oncology · 178
PDF
Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial
2012 · Stefan Faderl, Meir Wetzler, et al. · Journal of Clinical Oncology · 176
Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom
2018 · Paul J. Bröckelmann, Suzanne McMullen, et al. · British Journal of Haematology · 55
PDF
Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas
2016 · Pier Luigi Zinzani, Vijayveer Bonthapally, et al. · Critical Reviews in Oncology/Hematology · 52
PDF
Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas
2016 · Pier Luigi Zinzani, Vijayveer Bonthapally, et al. · Critical Reviews in Oncology/Hematology · 33
PDF
Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma
2013 · Ajay K. Gopal, Robert Chen, et al. · Blood · 30
Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma
2013 · Barbara Pro, Ranjana H. Advani, et al. · Blood · 29
Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi‐agent chemotherapy
2018 · Jan Walewski, Andrzej Hellmann, et al. · British Journal of Haematology · 27
Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse
2015 · John Sweetenham, Jan Walewski, et al. · Blood · 23
Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
2022 · Justin Watts, Michael Maris, et al. · Blood · 22
Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
2016 · Barbara Pro, Ranjana H Advani, et al. · Blood · 22
OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)
2017 · Taofeek Owonikoko, Kristiaan Nackaerts, et al. · Journal of Thoracic Oncology · 21
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data
2015 · Vijayveer Bonthapally, Eric Wu, et al. · Current Medical Research and Opinion · 21
Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia
2017 · Xiaofei Zhou, Diane R. Mould, et al. · British Journal of Clinical Pharmacology · 20
PDF
Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
2014 · Barbara Pro, Ranjana Advani, et al. · Blood · 19
Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor
2017 · Huifeng Niu, Hyunjin Shin, et al. · EBioMedicine · 18
PDF
Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse
2016 · John W. Sweetenham, Jan Walewski, et al. · Transplantation and Cellular Therapy · 18
The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma
2015 · Craig H. Moskowitz, Auayporn Nadamanee, et al. · Transplantation and Cellular Therapy · 18
Works count: 59
Citation count: 4,170
H-index: 20
I10-index: 32
Year
Topic
Type